Next Article in Journal
Human Antimicrobial Peptides and Proteins
Previous Article in Journal
Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2014, 7(5), 530-544; doi:10.3390/ph7050530

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey

1
MercyHealth-ClinXus LLC, 260 Jefferson St., Grand Rapids, MI 49503, USA
2
Broward Health Medical Center, 1625 SE 3rd Ave. #525, Ft. Lauderdale, FL 33314, USA
3
Pfizer Inc., 235 East 42nd St., New York, NY 10017, USA
*
Author to whom correspondence should be addressed.
Received: 23 December 2013 / Revised: 25 March 2014 / Accepted: 29 April 2014 / Published: 7 May 2014
View Full-Text   |   Download PDF [135 KB, uploaded 7 May 2014]

Abstract

Biologics such as rituximab are an important component of oncology treatment strategies, although access to such therapies is challenging in countries with limited resources. This study examined access to rituximab and identified potential barriers to its use in the United States, Mexico, Turkey, Russia, and Brazil. The study also examined whether availability of a biosimilar to rituximab would improve access to, and use of, rituximab. Overall, 450 hematologists and oncologists completed a survey examining their use of rituximab in patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Less than 40% of physicians considered rituximab as easy to access from a cost perspective. Furthermore, many physicians chose not to treat, were unable to treat, or had to modify treatment with rituximab despite guidelines recommending its use in NHL and CLL patients. Insurance coverage, reimbursement, and cost to patient were commonly reported as barriers to the use of rituximab. Across all markets, over half of physicians reported that they would increase use of rituximab if a biosimilar was available. We conclude that rituximab use would increase across all therapy types and markets if a biosimilar was available, although a biosimilar would have the greatest impact in Brazil, Mexico, and Russia. View Full-Text
Keywords: rituximab; biosimilar; access; emerging markets rituximab; biosimilar; access; emerging markets
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Baer II, W.H.; Maini, A.; Jacobs, I. Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey. Pharmaceuticals 2014, 7, 530-544.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top